This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Buy Walmart Stock for Growth and Safety Before Q3 Earnings?
by Benjamin Rains
Walmart's drive to compete in an age where consumers want as many options as possible sets it up nicely for the future...
3 Reasons to Bet on Healthcare ETFs
by Sanghamitra Saha
The broader medical sector should be in the spotlight now on hopes of a coronavirus vaccine and the likelihood of a divided congress.
Will Vaccine Help Mastercard (MA) Regain Its Lost Business?
by Zacks Equity Research
The COVID-19 vaccine formulated by Pfizer is likely to help relieve the fear against travelling in crowds. This should spur travel demand and aid Mastercard (MA) to recover the lost cross-border sales.
AstraZeneca's (AZN) Calquence Fails in Coronavirus Study
by Zacks Equity Research
AstraZeneca's (AZN) BTK inhibitor drug Calquence fails to achieve the main goal in the phase II CALAVI studies for patients hospitalized with respiratory symptoms of COVID-19.
Moderna (MRNA) Up on Coronavirus Vaccine Candidate Progress
by Zacks Equity Research
Moderna ((MRNA) is set for the first interim analysis of its late-stage coronavirus vaccine study. Positive data may support an emergency use authorization by the end of 2020. Stock up.
Sector ETFs & Stocks to Buy This November
by Sweta Killa
November has been the second-best month for the Dow Jones since 1950, the Nasdaq since 1971 and Russell 2000 since 1979. The month is the best for the S&P 500 since 1950.
Stock Market News for Nov 12, 2020
by Zacks Equity Research
Stocks ended mostly higher on Wednesday, with the tech sector recovering from the losses made earlier in the week, after growing cases of coronavirus once again raised fears in the minds of investors.
The Zacks Analyst Blog Highlights: Pfizer, Visa, Mastercard, American Express and Discover Financial Services
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Visa, Mastercard, American Express and Discover Financial Services
Pfizer (PFE) to Supply 200M Doses of COVID-19 Vaccine to EU
by Zacks Equity Research
Pfizer (PFE) and BioNTech sign a supply deal with the European Union for up to 300 million doses of their coronavirus vaccine.
3 Cheap Tech Stocks Under $10 to Buy on Bullish Vaccine Outlook
by Benjamin Rains
Let's dive into three tech stocks that are trading for under $10 per share that investors might want to buy amid broader bullish vaccine sentiment in the market...
Equilibrium Descends on Mixed Market Indexes: AAPL, DIS & More
by Mark Vickery
The re-balancing from a big rush out of tech into cyclical stocks earlier this week was in play Wednesday.
ETFs to Consider on Pfizer's Vaccine Announcement
by Sejuti Banerjea
ETFs with exposure to Pfizer (PFE) are beginning to look good after the results of BNT162b2's Phase 3 trial.
Bet Big on Industrial Metal ETFs on Vaccine Optimism
by Sanghamitra Saha
Wall Street has been on a rallying mode in recent sessions on upbeat vaccine data and recovering global manufacturing activities.
Biggest ETF Winners from Coronavirus Vaccine News
by Neena Mishra
Promising vaccine results from Pfizer sent economically sensitive stocks soaring
Airline Stock Roundup: UAL & JBLU's Thanksgiving Plans, Azul's Traffic & More
by Maharathi Basu
JetBlue (JBLU) and United Airlines (UAL) intend to add flights to meet the anticipated demand swell during Thanksgiving. Meanwhile, Alaska Air's (ALK) CEO will call it quits next year.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, AstraZeneca and Johnson & Johnson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, AstraZeneca and Johnson & Johnson
Merck's (MRK) Keytruda Combo Meets Goal in Kidney Cancer Study
by Zacks Equity Research
Merck (MRK) and partner Eisai report positive top-line data from the phase III study evaluating Keytruda plus the latter's Lenvima for first-line treatment of patients with kidney cancer.
Stock Market News for Nov 11, 2020
by Zacks Equity Research
Wall Street had a mixed day on Tuesday with investor rushing to sell of tech stocks that had had dream run during the virus-induced lockdown, while they put money on sectors that took a beating during the pandemic.
Zacks Investment Ideas feature highlights: Pfizer, BioNTech, Peloton Interactive, AMC Entertainment and Etsy
by Zacks Equity Research
Zacks Investment Ideas feature highlights: Pfizer, BioNTech, Peloton Interactive, AMC Entertainment and Etsy
Arrow Electronics, Clipper Realty, Pfizer, BioNTech and Moderna highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Arrow Electronics, Clipper Realty, Pfizer, BioNTech and Moderna highlighted as Zacks Bull and Bear of the Day
Vaccine Hopes Rise as Pharma Giants Inch Closer Toward Success
by Ritujay Ghosh
Stocks of Eli Lilly and Company (LLY), Pfizer, Inc. (PFE) and Moderna, Inc. (MRNA) have been in focus since the coronavirus outbreak as they have been the frontrunners in the vaccine race.
Vaccine News Lifts Energy Stocks Higher: 5 Stocks to Watch
by Zacks Equity Research
COVID-19 vaccine news aid energy stocks in moving higher making it judicious to watch out for prominent names like Oasis Petroleum (OASPQ) and PDC Energy (PDCE)
Vaccine Hopes Drive Demand for Value Stocks: 5 Picks
by Tirthankar Chakraborty
Value stocks are in favor now on vaccine hopes, which calls for investing in Red Robin Gourmet Burgers (RRGB), Matson (MATX), Malibu Boats (MBUU), Farmers National Banc (FMNB) and Northrim BanCorp (NRIM).
Leveraged ETF Areas That Gained the Most on Vaccine Hopes
by Sanghamitra Saha
Wall Street spiked on Nov 9 on news that a Pfizer and BioNTech vaccine candidate was more than 90% effective in avoiding COVID-19 in its clinical trial.
Vaccine Hopes & Divided Government: Sector ETFs to Win
by Sanghamitra Saha
News that a Pfizer and BioNTech vaccine candidate was more than 90% effective in avoiding COVID-19 in its clinical trial has instilled more optimism in the markets.